coiaward2010

Now also in Spanish: CML patients' declaration on quality and consistency in use of generics

An important topic of increasing attention discussed between CML patients and health professionals is the introduction of generics in CML treatment. Patients welcome that generics may improve patient access to more affordable therapies in many countries. However, patients also raise concerns about impact on their cancer when switched between different products for non-medical reasons, if their equivalence in terms of quality and efficacy is uncertain.

In May 2014, CML patient groups published a declaration calling governments, health authorities and healthcare professionals to minimize potential uncertainties and risks for patients with five measures. Thanks to our friends at Fundación Colombiana de Leucemia y Linfoma and the Max Foundation, a Spanish translation of the declaration is now available. See also our Generics knowledge base which is continuously updated.


 
   
 

EU e-Privacy Directive

Please donate!

Please donate!

LogIn

Tweet Feed

cmlnet
Check our global database run by patients for #patients with 51 current #CML #clinicaltrials which have been initia… twitter.com/i/web/status/9…

Thursday, 24 May 2018

ZPWLC
“When looking at statistics, it is important to remember that we are not talking about decimal points on a graph, b… twitter.com/i/web/status/9…

Retweeted Thursday, 24 May 2018

LMC_PACIENTES
From 26 April “Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chron… twitter.com/i/web/status/9…

Retweeted Saturday, 19 May 2018